key: cord-1019087-f73ic2ov
authors: Moretto, F.; Sixt, T.; Devilliers, H.; Abdallahoui, M.; Eberl, I.; Rogier, T.; Buisson, M.; Chavanet, P.; Duong, M.; Esteve, C.; Mahy, S.; Salmon-Rousseau, A.; Catherine, F.; Blot, M.; Piroth, L.
title: Is there a need to widely prescribe antibiotics in patients hospitalized for COVID-19?
date: 2021-01-27
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.01.051
sha: cb60aa8ba162c07f772639b7196532ff88eaf272
doc_id: 1019087
cord_uid: f73ic2ov

BACKGROUND: The usefulness and benefits of wide antimicrobial therapy prescription in patients hospitalized for COVID-19 is debated. METHODS: All patients hospitalized in the infectious diseases department of Dijon (France) between the 27(th) of February and the 30(th) of April 2020 for a confirmed COVID-19 were included. Clinical, biological and radiological data were collected, as well as treatments and outcomes. An unfavorable outcome was defined as death or transfer to intensive care unit. We compared the characteristics and outcomes between patients with and without antibiotics using propensity score matching. FINDINGS: Among the 222 patients included, 174 (78%) were on antibiotics. The univariate analysis showed that patients with antibiotics were significantly older, frailer and with a more severe presentation at admission. An unfavorable outcome was more frequent in patients with antibiotic therapy (HR = 2.94, CI95%: 1.07-8.11; p = 0.04). In multivariate analysis and on propensity score, antibiotic therapy was not significantly associated with outcome (HR = 1.612, CI95%: 0.562-4.629, p = 0.37). CONCLUSION: Antibiotics were frequently prescribed in our study and associated with a more severe presentation at admission. However, receiving antibiotics was not associated with outcome, either after adjustment on a propensity score. In line with recent publication, such data argue for streamlining of antibiotic therapies in COVID-19 patients.

defined as death or transfer to intensive care unit. We compared the characteristics and outcomes between patients with and without antibiotics using propensity score matching.

Findings: Among the 222 patients included, 174 (78%) were on antibiotics. The univariate analysis showed that patients with antibiotics were significantly older, frailer and with a more severe presentation at admission. An unfavorable outcome was more frequent in patients with antibiotic therapy (HR=2.94, CI95%: 1.07-8.11; p=0.04). In multivariate analysis and on propensity score, antibiotic therapy was not significantly associated with outcome (HR=1.612, CI95%: 0.562-4.629, p=0.37).

SARS-CoV2 infection, also called COVID-19, is an emergent viral infection caused by a similar virus as SARS-CoV1 which was responsible for many cases of severe acute respiratory syndrome (SARS) in 2003

with a high mortality. The SARS-CoV2 was discovered in December 2019 in China , and is spreading worldwide as a pandemic, reaching France in January 2020 (Lescure et al., 2020) .

In many cases, the clinical presentation of COVID-19 is mild to moderate with flu-like symptoms (Guan et al., 2020; Lechien et al., 2020) . At the beginning of the epidemic, nearly 60% of patients were hospitalized (French Public Health, 2020), especially for the management of viral pneumonia with the need of oxygen supplementation (Aggarwal et al., 2020) . Nearly a quarter of them worsen and developed an acute respiratory distress syndrome (ARDS), were admitted in intensive care unit (ICU) and required oxygen (Richardson et al., 2020; Wiersinga et al., 2020; Wu and McGoogan, 2020) . The mortality is low, but the real rate is not yet well-known (between 2-3% in China (Guan et al., 2020; Wu and McGoogan, 2020) and nearly 20% in studies in the United States (Aggarwal et al., 2020) ). The rate of mortality among patients who are not hospitalized, is not well-known. This rate may increase in hospitalized patients and even more in patients managed in ICU.

The best way to manage the patients hospitalized for COVID-19 is still to be determined. Although some treatments as corticoids, have showed good results, few therapeutic options are available with a proved efficacy and safety in clinical trials (Horby et al., 2020; Toniati et al., 2020) . There are currently J o u r n a l P r e -p r o o f thousands of clinical trials to study this new disease, included its treatment. However, there is no clinical trial about the efficacy of antibiotics in COVID-19 for the moment.

Whether antibiotics are part of the optimal management of these patients has been debated from the very beginning of the epidemic. Indeed, it has been initially feared that, as for influenza, COVID-19 could be associated with bacterial co-or super-infections (especially with Staphylococcus aureus and Streptococcus pneumoniae) which may legitimate the use of antibiotics. Since that time, no or few bacterial infections were found to be associated with COVID-19 (Garcia-Vidal et al., 2020; Rawson et al., 2020) , thus leading many national guidelines not to recommend systematic empiric antibiotic therapy in patients hospitalized with COVID-19 (French Public Health Comittee, 2020). Nevertheless, many patients are still treated by antibiotics (Rawson et al., 2020) and there is no clinical study assessing the potential usefulness of empiric antibiotic therapy in patients hospitalized with COVID-19.

We conducted a retrospective study and compared the characteristics and outcomes between hospitalized patients with and without antibiotic therapy using propensity score (PS) matching.

All the patients aged 18 and beyond, who were hospitalized in the Infectious Diseases Department of the University Hospital of Dijon (France) for a confirmed COVID-19 between the 27 th of February and the 30 th of April 2020 (during the first peak of the epidemic in France) were included.

A case of COVID-19 was defined as a positive result of real time polymerase chain reaction (RT-PCR) assay on either nasopharyngeal swab or sputum sample. Patients were excluded if they were admitted from ICU.

Patients' consents were not obtained given the retrospective nature of this study not making it mandatory under French law.

For each patient, epidemiological, demographic, clinical, biological, radiological, treatment and outcomes were collected from medical records.

The comorbidities and clinical signs which were systematically collected are summarized in Table 1 (Du et al., 2020) . The Charlson Comorbidity Index (CCI) with and without age was also assessed.

The clinical signs (presented by the patient at the admission to hospital) which were systematically collected were summarized in Table 2 . Biological data were also collected at the time of admission: neutrophils, lymphocytes, fibrinogen, C-reactive protein, albumin, prealbumin, creatinine, glomerular filtration rate, urea, alanine aminotransferase. CT-scan data were finally taken with use of a severity classification (non evocative: 0%, minimal: 0 -15%, moderate: 15-25%, extent: 25-50%, severe: 50-75%, critical: more than 75%).

For each patient, three clinical scores were calculated: the National Early Warning Score 2 (NEWS2) (Mellhammar et al., 2019) , the Quick Sepsis-related Organ Failure Assessment (qSOFA) (Goulden et al., 2018; Singer et al., 2016) J o u r n a l P r e -p r o o f

The outcomes were collected for each patient until the 28 th day after the admission to the hospital, as follows: discharged alive, dead, transferred in ICU. An unfavourable outcome was defined as death or transfer to ICU during the 28 days following admission.

A univariate analysis was first performed to compare the patients with and without antibiotics. Survival curves and hazard ratio (HR) were calculated with log rank test.

As a primary analysis, a multivariate analysis on complete data with the Cox model was performed. The analysis was adjusted on baseline variables which were clinically relevant or statistically linked to the principal outcome. A step by step descending model was used. The candidates as adjustment variables are summarized in Figure 1 . HR with interval confidence 95% (CI95%) were calculated.

As a sensitivity analysis, we computed a second Cox model with a propensity score (PS) matching. The PS was calculated by the mean of a logistic regression model including antibiotic prescription as the dependant variable, and all relevant clinical and biological variables as independent variables. When some biological data were missing, data imputation by multiple imputation method was performed for propensity score estimate. Then, a Cox regression on complete data weighted by 1-propensity score was done (a patient with a score of 0.1 is weighted 0.9 and a patient with a score of 0.9 is weighted 0.1). The model included the same covariates entered in the primary analysis.

Statistical analyses were performed using SAS software. A p<.05 was considered as significant.

In this study, 222 patients were included. Except for the patients who were transferred from ICU, all patients were included, without loss of follow-up during the 28 days following hospital admission.

Among of 222 patients, 174 (78%) were on an antibiotic therapy. The characteristics of the population on antibiotics are described in Table 1 and 2. The median (interquartile range (IQR)) delay between the onset of symptoms and hospitalization was 6.0 (3.0, 9.0) days. The clinical signs that were most frequently found were fever (143, 82%), cough (120, 69%) and dyspnea (118, 68%). Most of patients with antibiotic therapy had moderate and extensive lesions on CT-scan, respectively 45 (32%) and 45 patients (32%). Severe lesions were found for 21 patients (15%) and critical lesions in 4 patients (3%).

Regarding the first line of antibiotic therapy, the most used antibiotic was amoxicillin-clavulanic acid (95, 55%) followed third generation cephalosporins with or without macrolides (25, 14% and 27, 16%, respectively) (Table 3) .

A unfavorable event (death or a transfer in ICU) was observed for 60 patients (34%) in the antibiotic therapy group, as compared with 4 patients (8%) in the group without antibiotics (HR=2.94 (CI95%: 1.07-8.11; p=0.04).

In the Cox multivariate regression, antibiotic therapy was not associated with the outcome (HR=1.612, CI95%: 0.562-4.629, p=0.37), when adjusting on cardiovascular diseases, dyspnea, specific COVID-19 treatment's prescription, class of NEWS2 at D0 and degree of CT-scan lesions (Figure 1 ). 

As for flu, antibiotics have been hypothesized to be needed in the management of COVID-19. The fear of bacterial co-or super-infections with a high mortality may have been the main reason that explains the very frequent prescription of antibiotics, especially at the beginning of the epidemic. In this retrospective study, we found a high rate of antibiotics' prescription reaching three quarters of our patients, as found in many studies published worldwide (Rawson et al., 2020) . We also showed that antibiotics' prescription was more frequent in some populations. Indeed, patients with antibiotic therapy were older and have more cardiovascular diseases. The initial clinical and biological presentation was more severe with a higher rate of fever, dyspnea and needing of oxygen supplementation. The thoracic CT-scan showed finally extensive lesions. So, patients who underwent antibiotics during their hospitalization were the frailer and with more severe initial presentation. This correlates with the management of patients who present with lower respiratory tract symptoms in A&E at times of flu epidemic. The higher the mortality risk, the more frequent prescription of antibiotics.

Currently, the rationale of antibiotics' prescription was only the parallel made with other viral infections, especially influenza virus. Indeed, in patients with flu, we face a high rate of bacterial (or fungal with aspergillosis) co-or super-infections (Klein et al., 2016; Metersky et al., 2012) . Staphylococcus aureus and Streptococcus pneumoniae are the main bugs found in these kinds of pneumoniae (Metersky et al., 2012) . It is also known that the prognosis of these coinfections could be poor, especially in elderly people which are the main population concerned by these infections (Metersky et al., 2012 ).

Yet, in the few cohorts dealing with this topic, the rate of bacterial coinfections was very low, even zero Another potential benefit of some antibiotics could be their anti-inflammatory properties, since the potential severity of the SARS-CoV2 infection is linked to a systemic inflammatory response (Mangalmurti and Hunter, 2020; Ragab et al., 2020) . Macrolides, such as azithromycin, are known to downregulate proinflammatory cytokines (Kuo et al., 2019; Ulrich and Pillat, 2020) , albeit with a potential clinical benefit in patients with flu (Lee et al., 2017) (especially in case of ARDS (Kawamura et al., 2018) ), but not in MERS-CoV infection (Arabi et al., 2019) . No clear specific effect could be demonstrated in the CoVID-19 context (Rizk et al., 2020) and, if any, could be counterbalanced by the weight of side effects (Ray et al., 2012) .

Herein, we found that antibiotics were not associated with a better outcome, with nearly same results using two different multivariate analyses (Cox model and propensity score matching). These two approaches should allow overrunning the negative impact of a more severe baseline presentation in patients on antibiotics. By contrast, the characteristics usually associated with poorer outcomes in other studies (Du et al., 2020) were also found in ours, in particular preexisting cardiovascular diseases, a higher NEWS2 at the admission and more severe lesions on CT-scan. More surprisingly, treatments given to specifically treat CoVID-19 were associated with a better prognosis. Most of these treatments were given as part of therapeutic research protocols, which may represent a selection bias. However, it could be advocated that such a bias should have limited impact in the multivariate analysis. A benefit of these treatments considered as a whole would be also surprising, since some of them were later on shown individually to have no or mild effect on the evolution of COVID-19. It is also unlikely that corticosteroids, whose interest in positively impacting survival has been recently pointed out (Horby et al., 2020) , would have impacted on the observed results since very few of our patients were on such adjunctive therapy.

This study has some limits. First, it concerns only patients hospitalized for COVID-19 in a medical ward, and not those in intensive care unit. It cannot be excluded that the impact of wide antibiotic use could be different in such a context. Second, microbiological documentation is very often missing, since antibiotics were often given early in the management of the patients, without previous documentation.

In case of undocumented genuine bacterial coinfection, it could also be speculated that the antibiotics used were not the right ones, even though they cover the main bacterial pathogens seen in a viral superinfection context. Last, it likely suffers from a lack of statistical power. Nevertheless, and as far as we know, this is one of the first studies about the prescription of antibiotics for the management of COVID-19 in a whole cohort with nearly full data available and assessable.

In conclusion, a high proportion of COVID-19 patients was treated by antibiotics in our population although no bacterial coinfection was documented (but infrequently looked for). The likelihood of these prescriptions was correlated with the severity of the COVID-19 and/or the frailty of the patients. Despite this, such wide antibiotics use does not appear to have significant global impact on the prognosis of patients hospitalized with COVID-19 in medical wards through lack of evidence of bacterial coinfection.

According to these data, antibiotic therapy may be not prescribed systematically for patients with COVID-19 but only in case of proved (or strong suspicion) of bacterial infection. Confirmation of these data is needed with clinical trials.

J o u r n a l P r e -p r o o f

Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States

Macrolides in critically ill patients with Middle East Respiratory Syndrome

CURB-65 Score is Equal to NEWS for Identifying Mortality Risk of Pneumonia Patients: An Observational Study

Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study

Guidelines concerning the use of antibiotics for the management of

Incidence of co-infections and superinfections in hospitalised patients with COVID-19: a retrospective cohort study

SIRS and NEWS for predicting inhospital mortality and ICU admission in emergency admissions treated as sepsis

Clinical Characteristics of Coronavirus Disease 2019 in China

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. Infectious Diseases (except HIV/AIDS)

Adjunctive therapy with azithromycin for moderate and severe acute respiratory distress syndrome: a retrospective, propensity score-matching analysis of prospectively collected data at a single center

The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis

Azithromycin suppresses Th1-and Th2-related chemokines IP-10/MDC in human monocytic cell line

Clinical and Epidemiological Characteristics of 1,420 European Patients with mild-to-moderate Coronavirus Disease

Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial

Clinical and virological data of the first cases of COVID-19 in Europe: a case series

Cytokine Storms: Understanding COVID-19

NEWS2 is Superior to qSOFA in Detecting Sepsis with Organ Dysfunction in the Emergency Department

Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza

The COVID-19 Cytokine Storm; What We Know So Far

Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Pharmaco-Immunomodulatory Therapy in COVID-19

The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in

CD147 as a Target for COVID-19 Treatment: Suggested Effects of Azithromycin and Stem Cell Engagement

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

A new coronavirus associated with human respiratory disease in China

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

We are thankful to all the doctors, residents, and medical students of the Infectious Diseases Department of the Dijon's teaching hospital for their help and all the work they did during the epidemic.We thank the virology laboratory for performing the SARS-CoV2 real time polymerase chain reaction (RT-PCR) assay. We thank the patients.We thank Dr Claire BRENIAUX (Doctoral Researcher in British Society and Politics and Teaching Fellow at the University of Burgundy) for her linguistic contribution.

None to declare.

None to declare.

None to declare. 143 (82) 120 (69) 118 (68) 59 (34) 53 (30) 32 (18) 10 (6) 17 (10) 26 (54) 26 (54) 19 (40) 23 (48) 13 (27) 6 (24) 6 (24) 8 (32) 3 (12) 1 (4) 1 (4) 0.01 1 Fever defined as a temperature higher than 38°C. 2 Degree of lesions on CT-scan: minimal (0-15%), moderate (15-25%), extensive (25-50%), severe (50-75%), critical (more than 75%).